Mineralys Therapeutics (MLYS) said Tuesday it has completed enrollment in the phase 2 trial of lorundrostat for the treatment of hypertension in subjects with chronic kidney disease and albuminuria.
The clinical-stage biopharmaceutical company said it continues to expect topline data from the trial in Q2 of 2025.
Price: 9.92, Change: -0.01, Percent Change: -0.10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.